Shares of MELA Sciences (MELA) are soaring post-session after receiving European CE Mark...

Shares of MELA Sciences (MELA) are soaring post-session after receiving European CE Mark approval for MelaFind, its device for evaluating and detecting melanoma, allowing the company to market it to dermatologists across the EU. Shares +32% AH.

Comments (2)
  • Adjusted Return
    , contributor
    Comments (396) | Send Message
    I don't know this company but do note that the CE mark is essentially a quality assurance verification procedure, even for medical devices; not an effectiveness test. In other words, it is not a real hurdle. I don't see why investors would be so excited but I guess it depends on what the company has been feeding them.
    7 Sep 2011, 03:52 AM Reply Like
  • jrusso9722
    , contributor
    Comments (131) | Send Message
    CE gives Mela the right to market MelaFind to physicians. That is a great opportunity, to present data to Doctors, discuss it with them, and hopefully sell it. I don't see the company feeding info.. Actually, I would like to see more information in print. To catch melanoma at it's earliest, most curable stage is very exciting. Advanced melanoma can literally destroy a body. My wife had a melanoma removed. Her life now, is constant observation. If MelaFind was available, questionable, but not obvious lesions could be scanned with a high probability of accuracy. When a person has, or has had melanoma, it affects the entire family. Early detection is key. A doctor does not read a MelaFind scan, such as one does with X-ray, mammogram, etc. MelaFind itself renders a response. To me, this is very exciting.
    16 Sep 2011, 05:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs